Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes

Franck Mauvais-Jarvis, Sabra L Klein, Ellis R Levin, Franck Mauvais-Jarvis, Sabra L Klein, Ellis R Levin

Abstract

Severe outcomes and death from the novel coronavirus disease 2019 (COVID-19) appear to be characterized by an exaggerated immune response with hypercytokinemia leading to inflammatory infiltration of the lungs and acute respiratory distress syndrome. Risk of severe COVID-19 outcomes is consistently lower in women than men worldwide, suggesting that female biological sex is instrumental in protection. This mini-review discusses the immunomodulatory and anti-inflammatory actions of high physiological concentrations of the steroids 17β-estradiol (E2) and progesterone (P4). We review how E2 and P4 favor a state of decreased innate immune inflammatory response while enhancing immune tolerance and antibody production. We discuss how the combination of E2 and P4 may improve the immune dysregulation that leads to the COVID-19 cytokine storm. It is intended to stimulate novel consideration of the biological forces that are protective in women compared to men, and to therapeutically harness these factors to mitigate COVID-19 morbidity and mortality.

Keywords: COVID-19; cytokine storm; estrogen; immunomodulation; progesterone; sex difference.

© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
Anti-inflammatory and immunomodulatory actions of estradiol and progesterone. High physiological concentrations of 17β-estradiol (E2) suppress the production of proinflammatory cytokines, for example, interleukin 6 (IL-6), interleukin 1β (IL-1β), and tumor necrosis factor α (TNF-α), and chemokine CCL2 by macrophages, thus preventing neutrophils and monocytes migration into inflamed areas. Progesterone (P4) also inhibits proinflammatory cytokines IL-1β and interleukin 12 production by macrophages and dendritic cells. High concentrations of E2 or P4 stimulate CD4+ T-helper cell production of anti-inflammatory cytokines, for example, interleukin 4 and interleukin 10, and favor Th2-type anti-inflammatory responses. E2 and P4 also enhance the expansion of regulatory T cells (Treg), thus promoting immune tolerance. Finally, E2 stimulates antibody production by B cells.

References

    1. Karlberg J, Chong DS, Lai WY. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? Am J Epidemiol. 2004;159(3):229-231.
    1. Alghamdi IG, Hussain II, Almalki SS, Alghamdi MS, Alghamdi MM, El-Sheemy MA. The pattern of middle east respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health. Int J Gen Med. 2014;7:417-423.
    1. Mauvais-Jarvis F, Bairey Merz CN, Barnes PJ, et al. . Sex and gender: modifiers of health, disease and medicine. Lancet. 2020;396.
    1. Guan WJ, Ni ZY, Hu Y, et al. . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.
    1. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775-1776.
    1. COVID-19 National Emergency Response Center, Epidemiology and Case Management Team, Korea Centers for Disease Control and Prevention. Coronavirus disease-19: the first 7755 cases in the Republic of Korea. Osong Public Health Res Perspect. 2020;11(2):85-90.
    1. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, and the Northwell COVID-19 Research Consortium Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-2059.
    1. Klein S, Dhakal S, Ursin R, Deshpante S, Sandberg K, Mauvais-Jarvis F. Biological sex impacts COVID-19 outcomes. PLoS Pathog. 2020;16(6):e1008570.
    1. Grasselli G, Zangrillo A, Zanella A, et al. ; for the COVID-19 Lombardy ICU Network Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-1581.
    1. Docherty AB, Harrison EM, Green CA, et al. . Features of 16 749 hospitalised UK patients with COVID-19 using the ISARIC WHO clinical characterisation protocol. [Published online ahead of print April 28, 2020.] medRxiv. Doi:10.1101/2020.04.23.20076042.
    1. Scully E, Haverfield J, Ursin R, Tannenbaum C, Klein SL. Sex is a variable in immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20:442-447.
    1. Marina S, Piemonti L. Gender and age effects on the rates of infection and deaths in individuals with confirmed SARS-CoV-2 infection in six European countries. SSRN website. or . Posted April 28, 2020. Accessed June 20, 2020.
    1. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517-528.
    1. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607-613.
    1. Chen G, Wu D, Guo W, et al. . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-2629.
    1. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
    1. Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959-970.
    1. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6):102537.
    1. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92(7):814-818.
    1. Leng Z, Zhu R, Hou W. Transplantation of ACE2– mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216-228.
    1. Butterworth M, McClellan B, Allansmith M. Influence of sex in immunoglobulin levels. Nature. 1967;214(5094):1224-1225.
    1. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010;10(5):338-349.
    1. Amadori A, Zamarchi R, De Silvestro G, et al. . Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med. 1995;1(12):1279-1283.
    1. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-638.
    1. Migeon BR. Females are Mosaics: X Inactivation and Sex Differences in Disease. 2nd ed. New York: Oxford University Press; November 12, 2013.
    1. Carrel L, Brown CJ. When the Lyon(ized chromosome) roars: ongoing expression from an inactive X chromosome. Philos Trans R Soc Lond B Biol Sci. 2017;372(1733):20160355.
    1. Tukiainen T, Villani AC, Yen A, et al. ; GTEx Consortium; Laboratory, Data Analysis &Coordinating Center (LDACC)—Analysis Working Group; Statistical Methods groups—Analysis Working Group; Enhancing GTEx (eGTEx) groups; NIH Common Fund; NIH/NCI; NIH/NHGRI; NIH/NIMH; NIH/NIDA; Biospecimen Collection Source Site—NDRI; Biospecimen Collection Source Site—RPCI; Biospecimen Core Resource—VARI; Brain Bank Repository—University of Miami Brain Endowment Bank; Leidos Biomedical—Project Management; ELSI Study; Genome Browser Data Integration &Visualization—EBI; Genome Browser Data Integration &Visualization—UCSC Genomics Institute, University of California Santa Cruz Landscape of X chromosome inactivation across human tissues. Nature. 2017;550(7675):244-248.
    1. Souyris M, Cenac C, Azar P, et al. . TLR7 escapes X chromosome inactivation in immune cells. Sci Immunol. 2018;3(19):eaap8855.
    1. Fink AL, Engle K, Ursin RL, Tang WY, Klein SL. Biological sex affects vaccine efficacy and protection against influenza in mice. Proc Natl Acad Sci U S A. 2018;115(49):12477-12482.
    1. Case LK, Wall EH, Dragon JA, et al. . The Y chromosome as a regulatory element shaping immune cell transcriptomes and susceptibility to autoimmune disease. Genome Res. 2013;23(9):1474-1485.
    1. Krementsov DN, Case LK, Dienz O, et al. . Genetic variation in chromosome Y regulates susceptibility to influenza A virus infection. Proc Natl Acad Sci U S A. 2017;114(13):3491-3496.
    1. Phiel KL, Henderson RA, Adelman SJ, Elloso MM. Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol Lett. 2005;97(1):107-113.
    1. Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28(5):521-574.
    1. Manolagas SC. Role of cytokines in bone resorption. Bone. 1995;17(2 Suppl 1):S63-S67.
    1. Shi L, Feng Y, Lin H, Ma R, Cai X. Role of estrogen in hepatocellular carcinoma: is inflammation the key? J Transl Med. 2014;12:93.
    1. Di Martino V, Lebray P, Myers RP, et al. . Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology. 2004;40(6):1426-1433.
    1. Naugler WE, Sakurai T, Kim S, et al. . Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317(5834):121-124.
    1. Speyer CL, Rancilio NJ, McClintock SD, et al. . Regulatory effects of estrogen on acute lung inflammation in mice. Am J Physiol Cell Physiol. 2005;288(4):C881-C890.
    1. Robinson DP, Lorenzo ME, Jian W, Klein SL. Elevated 17β-estradiol protects females from influenza A virus pathogenesis by suppressing inflammatory responses. PloS Pathog. 2011;7(7):e1002149.
    1. Robinson DP, Hall OJ, Nilles TL, Bream JH, Klein SL. 17β-estradiol protects females against influenza by recruiting neutrophils and increasing virus-specific CD8 T cell responses in the lungs. J Virol. 2014;88(9):4711-4720.
    1. Vermillion MS, Ursin RL, Attreed SE, Klein SL. Estriol reduces pulmonary immune cell recruitment and inflammation to protect female mice from severe influenza. Endocrinology. 2018;159(9):3306-3320.
    1. Peretz J, Pekosz A, Lane AP, Klein SL. Estrogenic compounds reduce influenza A virus replication in primary human nasal epithelial cells derived from female, but not male, donors. Am J Physiol Lung Cell Mol Physiol. 2016;310(5):L415-L425.
    1. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol. 2017;198(10):4046-4053.
    1. Dyall J, Coleman CM, Hart BJ, et al. . Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58(8):4885-4893.
    1. Johansen LM, Brannan JM, Delos SE, et al. . FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med. 2013;5(190):190ra79.
    1. Piccinni MP, Giudizi MG, Biagiotti R, et al. . Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J Immunol. 1995;155(1):128-133.
    1. Szekeres-Bartho J, Wegmann TG. A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. J Reprod Immunol. 1996;31(1-2):81-95.
    1. Hall OJ, Limjunyawong N, Vermillion MS, et al. . Progesterone-based therapy protects against influenza by promoting lung repair and recovery in females. PloS Pathog. 2016;12(9):e1005840.
    1. Gordon DE, Jang GM, Bouhaddou M, et al. . A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459-468.
    1. Robinson DP, Klein SL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm Behav. 2012;62(3):263-271.
    1. Doria A, Iaccarino L, Arienti S, et al. . Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reprod Toxicol. 2006;22(2):234-241.
    1. Szekeres-Bartho J, Faust Z, Varga P, Szereday L, Kelemen K. The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production. Am J Reprod Immunol. 1996;35(4):348-351.
    1. Pazos M, Sperling RS, Moran TM, Kraus TA. The influence of pregnancy on systemic immunity. Immunol Res. 2012;54(1-3):254-261.
    1. Qiancheng X, Jian S, Lingling P, et al. . Coronavirus disease 2019 in pregnancy. Int J Infect Dis. 2020;95:376-383.
    1. Chen L, Li Q, Zheng D, et al. . Clinical characteristics of pregnant women with Covid-19 in Wuhan, China. N Engl J Med. 2020;382(25):e100.
    1. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, et al. . Maternal death due to COVID-19 Disease. Am J Obstet Gynecol. 2020;223(1):109.e1-109.e16.
    1. Bernard-Poenaru O, Roux C, Blanqué R, Gardner C, de Vemejoul MC, Cohen-Solal ME. Bone-resorbing cytokines from peripheral blood mononuclear cells after hormone replacement therapy: a longitudinal study. Osteoporos Int. 2001;12(9):769-776.
    1. Rachoń D, Myśliwska J, Suchecka-Rachoń K, Wieckiewicz J, Myśliwski A. Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. J Endocrinol. 2002;172(2):387-395.
    1. Puder JJ, Freda PU, Goland RS, Wardlaw SL. Estrogen modulates the hypothalamic-pituitary-adrenal and inflammatory cytokine responses to endotoxin in women1. J Clin Endocrinol Metab. 2001;86(6):2403-2408.
    1. Aune B, Øian P, Omsjø I, Østerud B. Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood—a beneficial effect on atherogenesis and thrombus formation? Am J Obstet Gynecol. 1995;173(6):1816-1820.
    1. Kim JH, Meyers MS, Khuder SS, et al. . Tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice. Mol Metab. 2014;3(2):177-190.
    1. Lovre D, Peacock E, Katalenich B, et al. . Conjugated estrogens and bazedoxifene improve β cell function in obese menopausal women. J Endocr Soc. 2019;3(8):1583-1594.
    1. Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA. Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. Endocr Rev. 2017;38(3):173-188.
    1. Porter VR, Greendale GA, Schocken M, Zhu X, Effros RB. Immune effects of hormone replacement therapy in post-menopausal women. Exp Gerontol. 2001;36(2):311-326.
    1. Levin ER, Hammes SR. Nuclear receptors outside the nucleus: extranuclear signalling by steroid receptors. Nat Rev Mol Cell Biol. 2016;17(12):783-797.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren